Portosystemic Encephalopathy

Portosystemic Encephalopathy

No Results

No Results


Portosystemic encephalopathy (PSE) or hepatic encephalopathy (HE) is a neuropsychiatric syndrome associated with hepatocellular failure or portosystemic venous shunting.

There has been a lack of standardization of terminology used to define hepatic encephalopathy. “Acute” hepatic encephalopathy referred to acute liver failure or acute decompensation in the setting of chronic liver failure. The term “chronic” was used to describe the hepatic encephalopathy seen in chronic liver failure.

In 2002, a working committee task force on hepatic encephalopathy standardized the definition and the classification of hepatic encephalopathy. According to the characteristics of neurologic manifestations, hepatic encephalopathy is classified as episodic (previously, “acute”), persistent (previously, “chronic”), or minimal (previously, “subclinical”).

Hepatic encephalopathy is also classified into three types based on the disease state of the liver, as follows:

Type A: Hepatic encephalopathy associated with acute liver failure

Type B: Hepatic encephalopathy associated with portosystemic bypass with no intrinsic hepatocellular disease

Type C: Hepatic encephalopathy associated with cirrhosis and portal hypertension or portosystemic shunts. In cases of chronic liver disease, type C hepatic encephalopathy can be episodic or persistent. The term “subclinical encephalopathy” was replaced with “minimal encephalopathy.”

Hepatic encephalopathy is a reversible metabolic encephalopathy with multifactorial pathogenesis. The widely accepted hypothesis is that encephalopathy is due to a failure of hepatic clearance of gut-derived toxins. Although the exact toxins involved remain controversial, ammonia remains the toxin of interest. This has led to many investigative and therapeutic efforts aimed at identifying and eliminating the putative toxin(s) that originate from the gut lumen. A fluctuating level of consciousness is common, and progression to coma may occur rapidly.

A high index of clinical awareness is critical for anticipating and recognizing complications. A precipitating cause is usually discovered after clinical and laboratory evaluations. Although elevated plasma ammonia levels are often seen and therapy based on this observation is generally effective, poor correlation exists between the plasma ammonia levels and the degree of encephalopathy. As noted, multiple mechanisms contribute to the pathogenesis of this disorder. Discrete neuropathologic features are described in PSE but these may represent epiphenomena. Treatment with lactulose is the mainstay of therapy, but novel developmental approaches show promise.

Although the exact pathophysiologic mechanisms of hepatic encephalopathy remain unclear, two areas have received more attention: first, the gut-derived neurotoxins (mainly ammonia) and, second, the changes in astrocyte morphology and physiology.

Hyperammonemia and portosystemic shunting led to the hypothesis in 1877 that enteral production of ammonia is central to the pathogenesis of this disorder. Various other putative toxins, which may also be shunted, may result in portosystemic encephalopathy (PSE), are described.

Portosystemic shunting is a requisite for the development of PSE. Although disturbances in urea cycle metabolism may cause hyperammonemia, similar encephalopathy does not exist in patients with isolated hyperammonemia in the absence of other evidence of hepatic dysfunction. The pathogenesis of portal hypertension is discussed in Portal Hypertension. This complex condition results in the flow of portal blood containing putative toxins produced in the gut to the systemic circulation and, ultimately, the brain via extrahepatic shunts (collateral flow).

A minority of patients with cirrhosis present with recurrent symptoms of hepatic encephalopathy often without any precipitating cause. These patients may have minimal or mild hepatocellular dysfunction but have significant neurologic impairment. In one study, large portosystemic shunts were detected by computed tomography scanning in most patients. Shunting, in part, appears to be a response to increased hepatic vascular resistance in the setting of cirrhosis; however, shunting may also result from other causes, including portal vein thrombosis or compression, congenital hepatic fibrosis, iatrogenic shunt placement, and congenital shunt formation. The latter is an important consideration in younger patients with otherwise unexplained hepatic encephalopathy (in the absence of cirrhosis or iatrogenic shunts or portosystemic shunts associated with splenic or portal vein thrombosis). These patients may present in middle age and respond to appropriate shunt-reversal surgery.

The intrahepatic shunt (transjugular intrahepatic portosystemic shunt [TIPS]) provides a conduit for portal venous blood to flow directly into the hepatic vein while bypassing the hepatic parenchyma. TIPS is associated with the development of PSE in approximately 25% of cases.

The proposed gut-derived toxins responsible for PSE include ammonia, phenols, thiols, and short-chain fatty acids. Other possible mediators include cytokines and bacterial endotoxins. The enteral production of gamma-aminobutyric acid (GABA) and endogenous benzodiazepines (BZPs) remains somewhat speculative, although alterations in GABA-receptor–mediated neurotransmission may play a role for other reasons. The GABA complex, when provided with an appropriate ligand, leads to the production of an inhibitory signal. Widespread inhibition of cortical function from excessive GABAergic signaling, therefore, has been postulated as a mechanism leading to PSE.

The thiols or mercaptans are small volatile molecules that characteristically are recognized by their pungent odor, which results from the inclusion of a sulfhydryl group. Accordingly, they may lead to the clinical presentation of fetor hepaticus; however, ammonia is the best contender for the most significant gut-derived neurotoxin, and the ammonia hypothesis, therefore, justifies elaboration.

Most successful forms of therapy are based on the concept of ammonia neurotoxicity. Elimination of ammoniagenic luminal bacteria with nonabsorbed antibiotics (eg, neomycin), luminal acidification with nonabsorbed sugars fermented by luminal bacteria (eg, lactulose), avoidance of constipation, and reduction in ammoniagenic substrate intake (eg, protein-restricted diets) support the ammonia hypothesis.

The production of ammonia from the bacterial expression of urease and metabolism of colonic protein accounts for most ammoniagenesis. The bulk of extracolonic ammonia production occurs in the kidneys. Renal failure may promote ammoniagenesis as a consequence of uremia, which increases the available substrate for urease. Ammonia is a neurotoxic compound that principally is eliminated in humans by its hepatic conversion to urea. Periportal hepatocytes in the liver primarily metabolize ammonia. Subsequently, urea is excreted in the urine. Residual ammonia in the hepatic sinusoidal circulation is converted to glutamine by perivenous hepatocytes expressing glutamine synthase.

Besides causing functional changes such as reduction in cerebral perfusion, ammonia may also be responsible for structural changes in the brains of patients with hepatic encephalopathy. In necropsy studies, brains of cirrhotic patients exhibit Alzheimer type II astrocytosis, characterized by swollen astrocytes with enlarged nuclei and chromatin displaced to the perimeter of the cell. Type II astrocytosis is hypothesized to be caused in part by the detoxification of ammonia. Astrocytes, the only cells in the brain that can metabolize ammonia, contain glutamine.

In vivo proton magnetic resonance spectroscopy (MRS) (1H-MRS) shows that astrocyte swelling without increases in intracerebral pressure may occur early in the pathogenesis of PSE.

Ultimately, the development of advanced PSE may be accompanied by cerebral edema, which may contribute to neurologic impairment. Although cerebral edema has its most obvious manifestations in the patient with fulminant hepatic failure (FHF), osmotically active substances do accumulate in the brains of patients without overt cerebral edema. An osmotically sensitive pool of myoinositol is released from astrocytes in response to osmotically induced astrocyte swelling. A depletion of myoinositol is shown by 1H-MRS in patients with chronic PSE, and it appears to correlate with an increase in the signal for glutamine and glutamate.

With the use of MRS, low-grade cerebral edema has been demonstrated in patients with cirrhosis and chronic hepatic encephalopathy.

Despite the demonstration of astrocyte swelling and osmotic phenomena, treatment of hepatic encephalopathy does not include the use of mannitol or hyperventilation unless cerebral edema is suspected, as in FHF. No established role currently exists for routine cerebral magnetic resonance imaging (MRI) or MRS in the evaluation of PSE. The data supporting the ammonia hypothesis in PSE development, therefore, are impressive and follow multiple lines of evidence. Indeed, the past decades have been remarkable for the recognition of ammonia as a key element in the pathogenesis of PSE. However, other small molecules also may contribute, and these theories are not mutually exclusive. Synergistic toxicity of ammonia and other agents likely is important.

Production of so-called false neurotransmitters may contribute significantly to PSE pathogenesis. Putative agents include octopamine and diazepam. Supplementation with branched-chain amino acids (BCAAs) such as isoleucine, leucine, and valine, and avoidance of aromatic amino acids, such as phenylalanine, tryptophan, and tyrosine, may lead to decreased production of false neurotransmitters; however, the clinical benefit of BCAA supplementation has never been demonstrated convincingly (see Diet).

Increased production of endogenous BZPs has been proposed. These agents may represent the best-defined PSE false transmitters; however, their precise role is somewhat unclear. These substances are believed to depress central nervous system (CNS) function by binding to specific high-affinity BZP sites on GABA-receptor complexes. The GABA complex, when provided with an appropriate ligand, leads to the production of an inhibitory signal. Therefore, widespread inhibition of cortical function from excessive GABAergic signaling has been postulated as a mechanism leading to PSE.

Broadly speaking, cytokines are substances produced and released by cells for communication with other cells. Interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) are important examples of immunomodulatory cytokines that are increased in the systemic circulation and possibly contribute to the pathogenesis of systemic hemodynamic events in portal hypertension. The rapidly diffusing nitrous oxide (NO) is grouped with these substances for the purposes of this discussion. Although not a cytokine in the strictest sense, NO plays an important, if ill-defined, role in mediating some of the significant communication events resulting from cytokine activation in advanced liver disease.

Endotoxemia, presumably in part from gut mucosal permeability, is demonstrated in cirrhosis with portal hypertension. Associated increased IL-1 and TNF-α concentrations and metabolites of NO in the systemic circulation also are reported. This suggests that shunting of proinflammatory substances from the gut lumen contributes to or perhaps initiates a cascade of events culminating in the hyperdynamic circulation typical of advanced liver disease.

Cerebral ischemia is another mechanism that contributes to PSE, although it may represent a consequence of ammonia toxicity. A loss of cerebral blood flow autoregulation reflexes may accompany the development of FHF; however, cerebral autoregulation, in general, is preserved in patients with cirrhosis if the mean arterial pressure is maintained above 70 mm Hg, even in severe cases of hepatic encephalopathy. In contrast, patients with advanced hepatic encephalopathy have reduced cortical blood flow and increased cerebral vascular resistance.

Precipitating factors that lead to clinical manifestations of portosystemic encephalopathy may be obvious; however, often a cause is not evident despite concerted efforts to identify one. The importance of trying to determine the precipitating cause cannot be overemphasized. Infection, specifically spontaneous bacterial peritonitis (SBP), is especially important to exclude. Several known causes are categorized below by their proposed mechanisms. In some cases, multiple mechanisms may be responsible.

Findings include the following:

Increased substrate (protein) for ammoniagenesis

Increased substrate (urea) for ammoniagenesis

Increased protein intake

Gastrointestinal bleeding



Renal failure

Increased catabolism of protein




Findings include the following:






Development of hepatocellular carcinoma

Worsened intrinsic liver disease

Drug toxicity

Superimposed viral hepatitis

Findings include the following:

Portal vein thrombosis

Transjugular intrahepatic portosystemic shunt formation

Surgical shunt formation

Spontaneous shunt formation

The following agents may cause portosystemic encephalopathy:





Other agents

Increased diffusion of ammonia across the blood-brain barrier may occur, potentially resulting in alkalosis, which promotes ammonium ion conversion to less polar and more diffusible ammonia.

Blood transfusion may be a factor. Increased ammoniagenesis from transfusions may not be entirely accurate and is possibly more a theoretical than practical concern. Glutaminase activity and generation of ammonia in stored cellular blood products (especially platelets) may conceivably lead to infusion of ammonia during transfusion.

The true incidence and prevalence figures for portosystemic encephalopathy are not available. This complication is a frequent and possibly inevitable feature of progressive and chronic liver disease.

No specific racial data apply.

Presumably, because alcoholic liver disease occurs with greater frequency in men compared to women, a higher proportion of patients appears to be male.

A variety of neurologic conditions common in elderly patients (eg, multiple cerebral infarcts, Alzheimer disease, parkinsonism) may exacerbate the manifestations of portosystemic encephalopathy; however, this condition usually is prominent in patients with advanced liver disease, which may not manifest in very elderly persons because they may not survive that long. No specific age frequency data are available.

In general, the prognosis of patients with advanced liver disease is poor unless they are able to undergo liver transplantation. The contribution that portosystemic encephalopathy makes to the decline of these individuals is limited and, rather than acting as a causal factor, it is essentially a marker of decompensated liver disease. As with other complications of chronic liver disease, survival likely correlates better with their Child-Pugh score than the outcome of the complication itself.

The development of portosystemic encephalopathy indicates decompensated liver disease and, therefore, other features of decompensation, such as impaired coagulation (eg, elevated prothrombin time/international normalized ratio), varices, ascites, and portal hypertension, must be sought. Indeed, these manifestations potentially lead to recognition of complications that may account for the development of portosystemic encephalopathy, such as spontaneous bacterial peritonitis (SBP) or gastrointestinal bleeding. In this setting, portosystemic encephalopathy will often manifest itself for the first time (acute portosystemic encephalopathy) or suddenly worsen (acute or chronic portosystemic encephalopathy). Identification of the factors responsible for precipitating acute hepatic encephalopathy usually is possible (see Etiology).

Because of the potential for rapid evolution to coma, close clinical monitoring and the anticipation of elective endotracheal intubation for airway protection and ventilatory support is essential. Impairment of consciousness poses the greatest threat to the patient with acute portosystemic encephalopathy and must be evaluated and managed most aggressively. Chronic portosystemic encephalopathy is a common feature of advanced liver disease and, if left untreated, may evolve into a more severe state without any obvious precipitants, although the course of events may be somewhat slower. The level of consciousness in these patients also may fluctuate significantly in an apparently spontaneous manner.

Respiratory and ventilatory insufficiency, and the failure to protect the airway with consequent aspiration are anticipated complications that should be avoided with endotracheal intubation.

Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010 Mar 25. 362(12):1071-81. [Medline].

Mullen KD, Poordad F, Rossaro L, et al. Long term efficacy and survival in patients treated with the gut-selective antibiotic rifaximin (550 mg BID) for the maintenance of remission from overt hepatic encephalopathy. Gastroenterol Hepatol. 2011. 7(6 Suppl 9):1-15.

McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev. 2011. (11):CD008716. [Medline].

Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol. 2012 Jul. 107(7):1043-50. [Medline].

Weiss N, Tripon S, Lodey M, et al, for the Brain-Liver Pitie-Salpetriere Study Group (BLIPS). Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study. Fundam Clin Pharmacol. 2017 Dec 14. [Medline].

Rahimi RS, Rockey DC. Hepatic encephalopathy: pharmacological therapies targeting ammonia. Semin Liver Dis. 2016 Feb. 36(1):48-55. [Medline].

Patidar KR, Bajaj JS. Covert and overt hepatic encephalopathy: diagnosis and management. Clin Gastroenterol Hepatol. 2015 Nov. 13(12):2048-61. [Medline].

Pockros P, Hassanein T, Vierling J, et al. Phase 2, multicenter, randomized study of AST-120 (spherical carbon adsorbent) vs. lactulose in the treatment of lowgrade hepatic encephalopathy. J Hepatol. 2009. 50(Suppl 1):S43-4.

Simon-Talero M, Garcia-Martinez R, Torrens M, et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol. 2013 Dec. 59(6):1184-92. [Medline].

Laleman W, Simon-Talero M, Maleux G, et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013 Jun. 57(6):2448-57. [Medline].

Albrecht J, Hilgier W, Rafalowska U. Activation of arginine metabolism to glutamate in rat brain synaptosomes in thioacetamide-induced hepatic encephalopathy: an adaptative response?. J Neurosci Res. 1990 Jan. 25(1):125-30. [Medline].

Amaral OB, Quevedo J, Walz R, et al. Flumazenil and hepatic encephalopathy. Hepatology. 1999 Apr. 29(4):1338-9. [Medline].

Amodio P, Del Piccolo F, Marchetti P, et al. Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology. 1999 Jun. 29(6):1662-7. [Medline].

Avallone R, Zeneroli ML, Venturini I, et al. Endogenous benzodiazepine-like compounds and diazepam binding inhibitor in serum of patients with liver cirrhosis with and without overt encephalopathy. Gut. 1998 Jun. 42(6):861-7. [Medline].

Bansky G, Meier PJ, Riederer E, et al. Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans. Gastroenterology. 1989 Sep. 97(3):744-50. [Medline].

Barbaro G, Di Lorenzo G, Soldini M, et al. Flumazenil for hepatic coma in patients with liver cirrhosis: an Italian multicentre double-blind, placebo-controlled, crossover study. Eur J Emerg Med. 1998 Jun. 5(2):213-8. [Medline].

Basile AS, Jones EA. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology. 1997 Jun. 25(6):1303-5. [Medline].

Bianchi GP, Marchesini G, Fabbri A, et al. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. J Intern Med. 1993 May. 233(5):385-92. [Medline].

Bickford RG, Butt HR. Hepatic coma: the electroencephalographic pattern. J Clin Invest. 1955 Jun. 34(6):790-9. [Medline]. [Full Text].

Bircher J, Buhrer M, Franz K, et al. [1st use of lactitol in the treatment of porto-systemic encephalopathy]. Schweiz Med Wochenschr. 1982 Sep 18. 112(38):1306-7. [Medline].

Bresci G, Parisi G, Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. Eur J Med. 1993 Aug-Sep. 2(7):414-6. [Medline].

Butterworth RF. Pathogenesis of acute hepatic encephalopathy. Digestion. 1998 Jul. 59 Suppl 2:16-21. [Medline].

Chan H, Hazell AS, Desjardins P. Neurotoxins generated in liver failure cause altered expression of genes coding for key astrocytic proteins. Hepatology. 1999. 30(4):234A.

Charlton MR. Branched chains revisited. Gastroenterology. 1996 Jul. 111(1):252-5. [Medline].

Child CG 3rd. Ligature of the portal vein (translation of original by Eck, 1877). Surg Gynecol Obstet. 1953. 375-6.

Conn HO. Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis. 1977 Jun. 22(6):541-50. [Medline].

Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology. 1977 Apr. 72(4 Pt 1):573-83. [Medline].

Costa E, Guidotti A. Diazepam binding inhibitor (DBI): a peptide with multiple biological actions. Life Sci. 1991. 49(5):325-44. [Medline].

Cordoba J, Minguez B. Hepatic encephalopathy. Semin Liver Dis. 2008 Feb. 28(1):70-80. [Medline].

Dasani BM, Sigal SH, Lieber CS. Analysis of risk factors for chronic hepatic encephalopathy: the role of Helicobacter pylori infection. Am J Gastroenterol. 1998 May. 93(5):726-31. [Medline].

de Bruijn KM, Blendis LM, Zilm DH, et al. Effect of dietary protein manipulation in subclinical portal-systemic encephalopathy. Gut. 1983 Jan. 24(1):53-60. [Medline].

Deschenes M, Dufresne MP, Bui B, et al. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites. Am J Gastroenterol. 1999 May. 94(5):1361-5. [Medline].

Eck NV. Ligature of the portal vein. Voen Med J St-Petersburg (Russo). 1877. 130:1-2.

Elkington SG, Floch MH, Conn HO. Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical trial. N Engl J Med. 1969 Aug 21. 281(8):408-12. [Medline].

Fabbri A, Magrini N, Bianchi G, et al. Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy. JPEN J Parenter Enteral Nutr. 1996 Mar-Apr. 20(2):159-64. [Medline].

Felipo V, Hermenegildo C, Montoliu C, et al. Neurotoxicity of ammonia and glutamate: molecular mechanisms and prevention. Neurotoxicology. 1998 Aug-Oct. 19(4-5):675-81. [Medline].

Ferenci P. Hepatic encephalopathy. McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J, eds. Textbook of Clinical Hepatology. Oxford, England: Oxford University Press; 1991. Vol 1: 473-83.

Fischer JE, Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet. 1971 Jul 10. 2(7715):75-80. [Medline].

Flannery DB, Hsia YE, Wolf B. Current status of hyperammonemic syndromes. Hepatology. 1982 Jul-Aug. 2(4):495-506. [Medline].

Genesca J, Gonzalez A, Segura R, et al. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol. 1999 Jan. 94(1):169-77. [Medline].

Germain L, Frexinos J, Louis A, et al. [Double blind study of lactulose in 8 patients with chronic hepatic encephalopathy after portocaval shunt]. Arch Fr Mal App Dig. 1973 Jun. 62(4):293-302. [Medline].

Girard G, Butterworth RF. Effect of portacaval anastomosis on glutamine synthetase activities in liver, brain, and skeletal muscle. Dig Dis Sci. 1992 Jul. 37(7):1121-6. [Medline].

Gitlin N. Hepatic encephalopathy. Zakim D, Boyer T, eds. Hepatology: a textbook of liver disease. 3rd ed. Philadelphia, Pa: WB Saunders; 1996. Vol 1: 605-17.

Groeneweg M, Gyr K, Amrein R, et al. Effect of flumazenil on the electroencephalogram of patients with portosystemic encephalopathy. Results of a double blind, randomised, placebo-controlled multicentre trial. Electroencephalogr Clin Neurophysiol. 1996 Jan. 98(1):29-34. [Medline].

Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology. 1993 Nov. 18(5):1139-43. [Medline].

Hassanein TI, Tofteng F, Brown RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007 Dec. 46(6):1853-62. [Medline].

Haussinger D, Laubenberger J, vom Dahl S, et al. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology. 1994 Nov. 107(5):1475-80. [Medline].

Hazell AS, Desjardins P, Butterworth RF. Chronic exposure of rat primary astrocyte cultures to manganese results in increased binding sites for the ‘peripheral-type’ benzodiazepine receptor ligand 3H-PK 11195. Neurosci Lett. 1999 Aug 13. 271(1):5-8. [Medline].

Howard ER. Encephalopathy without cirrhosis: hunt the shunt. Gut. 1999 Sep. 45(3):329-30. [Medline].

Haussinger D. Hepatic glutamine transport and metabolism. Adv Enzymol Relat Areas Mol Biol. 1998. 72:43-86. [Medline].

Haussinger D. Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology. 2006 Jun. 43(6):1187-90. [Medline].

Ito S, Miyaji H, Azuma T, et al. Hyperammonaemia and Helicobacter pylori. Lancet. 1995 Jul 8. 346(8967):124-5. [Medline].

Jalan R, Olde Damink SW, Hayes PC, et al. Diagnosis of hepatic encephalopathy: will in vivo proton MRS play a role?. Hepatology. 1999 May. 29(5):1605-7. [Medline].

Jenkins RL, Gedaly R, Pomposelli JJ, et al. Distal splenorenal shunt: role, indications, and utility in the era of liver transplantation. Arch Surg. 1999 Apr. 134(4):416-20. [Medline].

Kale RA, Gupta RK, Saraswat VA, et al. Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy. Hepatology. 2006 Apr. 43(4):698-706. [Medline].

Keeling PW, Jones RB, Hilton PJ, et al. Reduced leucocyte zinc in liver disease. Gut. 1980 Jul. 21(7):561-4. [Medline].

Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology. 1997 Jun. 25(6):1351-60. [Medline].

Kircheis G, Quack G, Erbler H. L-ornithine L-aspartate in the treatment of hyperammonemia and hepatic encephalopathy. Conn HO, Bircher J, eds. Hepatic encephalopathy: syndromes and therapies. Bloomington, Ill: Medi-Ed; 1994. 373-83.

Kullmann F, Hollerbach S, Holstege A, et al. Subclinical hepatic encephalopathy: the diagnostic value of evoked potentials. J Hepatol. 1995 Jan. 22(1):101-10. [Medline].

Kostler H. Proton magnetic resonance spectroscopy in portal-systemic encephalopathy. Metab Brain Dis. 1998 Dec. 13(4):291-301. [Medline].

Larsen FS, Ejlersen E, Clemmesen JO. Preservation of cerebral oxidative metabolism in fulminant hepatic failure: an autoregulation study. Liver Transpl Surg. 1996 Sep. 2(5):348-53. [Medline].

Larsen FS, Olsen KS, Ejlersen E, et al. Cerebral blood flow autoregulation and transcranial Doppler sonography in patients with cirrhosis. Hepatology. 1995 Sep. 22(3):730-6. [Medline].

Lata J, Hulek P, Fejfar T, et al. [Rifaximin in the treatment of hepatic encephalopathy]. Vnitr Lek. 2002 Jun. 48(6):578-82. [Medline].

Laubenberger J, Haussinger D, Bayer S, et al. Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology. 1997 May. 112(5):1610-6. [Medline].

Layrargues GP, Rose C, Spahr L, et al. Role of manganese in the pathogenesis of portal-systemic encephalopathy. Metab Brain Dis. 1998 Dec. 13(4):311-7. [Medline].

Lee FY, Lu RH, Tsai YT, et al. Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation. Scand J Gastroenterol. 1996 May. 31(5):500-5. [Medline].

Lee JH, Seo DW, Lee YS, et al. Proton magnetic resonance spectroscopy (1H-MRS) findings for the brain in patients with liver cirrhosis reflect the hepatic functional reserve. Am J Gastroenterol. 1999 Aug. 94(8):2206-13. [Medline].

Lockwood AH. Early detection and treatment of hepatic encephalopathy. Curr Opin Neurol. 1998 Dec. 11(6):663-6. [Medline].

Lockwood AH, Yap EW, Rhoades HM, et al. Altered cerebral blood flow and glucose metabolism in patients with liver disease and minimal encephalopathy. J Cereb Blood Flow Metab. 1991 Mar. 11(2):331-6. [Medline].

Lockwood AH, Yap EW, Wong WH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab. 1991 Mar. 11(2):337-41. [Medline].

Loguercio C, Abbiati R, Rinaldi M, et al. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol. 1995 Jul. 23(1):39-46. [Medline].

Manzoni O, Prezeau L, Marin P, et al. Nitric oxide-induced blockade of NMDA receptors. Neuron. 1992 Apr. 8(4):653-62. [Medline].

Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003 Jan. 38(1):51-8. [Medline].

Mehndiratta MM, Sood GK, Sarin SK, et al. Comparative evaluation of visual, somatosensory, and auditory evoked potentials in the detection of subclinical hepatic encephalopathy in patients with nonalcoholic cirrhosis. Am J Gastroenterol. 1990 Jul. 85(7):799-803. [Medline].

Mendenhall CL, Rouster S, Marshall L, et al. A new therapy for portal systemic encephalopathy. Am J Gastroenterol. 1986 Jul. 81(7):540-3. [Medline].

Michalopoulos GK, DeFrances MC. Liver regeneration. Science. 1997 Apr 4. 276(5309):60-6. [Medline].

Montague PR, Gancayco CD, Winn MJ, et al. Role of NO production in NMDA receptor-mediated neurotransmitter release in cerebral cortex. Science. 1994 Feb 18. 263(5149):973-7. [Medline].

Moore JW, Dunk AA, Crawford JR, et al. Neuropsychological deficits and morphological MRI brain scan abnormalities in apparently healthy non-encephalopathic patients with cirrhosis. A controlled study. J Hepatol. 1989 Nov. 9(3):319-25. [Medline].

Moorman AF, Vermeulen JL, Charles R, et al. Localization of ammonia-metabolizing enzymes in human liver: ontogenesis of heterogeneity. Hepatology. 1989 Mar. 9(3):367-72. [Medline].

Morgan MH, Read AE, Speller DC. Treatment of hepatic encephalopathy with metronidazole. Gut. 1982 Jan. 23(1):1-7. [Medline].

Morgan MY. Cerebral magnetic resonance imaging in patients with chronic liver disease. Metab Brain Dis. 1998 Dec. 13(4):273-90. [Medline].

Morgan MY, Jakobovits AW, James IM, et al. Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. Gastroenterology. 1980 Apr. 78(4):663-70. [Medline].

Mullen KD, Szauter KM, Kaminsky-Russ K. “Endogenous” benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet. 1990 Jul 14. 336(8707):81-3. [Medline].

Ong J, Kerr DI. Clinical potential of GABAB receptor modulators. CNS Drug Rev. 2005 Autumn. 11(3):317-34. [Medline].

Perney P, Butterworth RF, Mousseau DD, et al. Plasma and CSF benzodiazepine receptor ligand concentrations in cirrhotic patients with hepatic encephalopathy: relationship to severity of encephalopathy and to pharmaceutical benzodiazepine intake. Metab Brain Dis. 1998 Sep. 13(3):201-10. [Medline].

Pogun S, Dawson V, Kuhar MJ. Nitric oxide inhibits 3H-glutamate transport in synaptosomes. Synapse. 1994 Sep. 18(1):21-6. [Medline].

Pomier-Layrargues G. TIPS and hepatic encephalopathy. Semin Liver Dis. 1996 Aug. 16(3):315-20. [Medline].

Pomier-Layrargues G, Giguere JF, Lavoie J, et al. Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial. Hepatology. 1994 Jan. 19(1):32-7. [Medline].

Quero JC, Hartmann IJ, Meulstee J, et al. The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis. Hepatology. 1996 Sep. 24(3):556-60. [Medline].

Rao VL, Butterworth RF. Neuronal nitric oxide synthase and hepatic encephalopathy. Metab Brain Dis. 1998 Sep. 13(3):175-89. [Medline].

Read AE, McCarthy CF, Heaton KW, et al. Lactobacillus acidophilus (enpac) in treatment of hepatic encephalopathy. Br Med J. 1966 May 21. 1(5498):1267-9. [Medline].

Riggio O, Efrati C, Catalano C, et al. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology. 2005 Nov. 42(5):1158-65. [Medline].

Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol. 2005 May. 42(5):674-9. [Medline].

Riggio O, Merlli M, Pedretti G, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. Dig Dis Sci. 1996 Mar. 41(3):578-84. [Medline].

Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med. 1997 Aug 14. 337(7):473-9. [Medline].

Rose C, Butterworth RF, Zayed J, et al. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology. 1999 Sep. 117(3):640-4. [Medline].

Rose C, Michalak A, Pannunzio P, et al. L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis. 1998 Jun. 13(2):147-57. [Medline].

Sandford SL, Tarter RE, Sclabassi R, et al. Sensory information processing in patients with nonalcoholic cirrhosis. Short-latency visual, auditory, and somatosensory event-related potentials. J Neurol Sci. 1987 Sep. 80(2-3):269-76. [Medline].

Sanyal AJ, Freedman AM, Shiffman ML, et al. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology. 1994 Jul. 20(1 Pt 1):46-55. [Medline].

Schumacher IK, Okamoto T, Kim BH, et al. Transplantation of conditionally immortalized hepatocytes to treat hepatic encephalopathy. Hepatology. 1996 Aug. 24(2):337-43. [Medline].

Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol. 1998 May. 28(5):856-64. [Medline].

Strauss E, Tramote R, Silva EP, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology. 1992 Dec. 39(6):542-5. [Medline].

Sushma S, Dasarathy S, Tandon RK, et al. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology. 1992 Jul. 16(1):138-44. [Medline].

Taylor-Robinson SD, Oatridge A, Hajnal JV, et al. MR imaging of the basal ganglia in chronic liver disease: correlation of T1-weighted and magnetisation transfer contrast measurements with liver dysfunction and neuropsychiatric status. Metab Brain Dis. 1995 Jun. 10(2):175-88. [Medline].

Unseld E, Krishna DR, Fischer C, et al. Detection of desmethyldiazepam and diazepam in brain of different species and plants. Biochem Pharmacol. 1989 Aug 1. 38(15):2473-8. [Medline].

Uribe M, Garcia-Ramos G, Ramos M, et al. Standard and higher doses of bromocriptine for severe chronic portal-systemic encephalopathy. Am J Gastroenterol. 1983 Aug. 78(8):517-22. [Medline].

Van der Rijt CC, Schalm SW, De Groot GH, et al. Objective measurement of hepatic encephalopathy by means of automated EEG analysis. Electroencephalogr Clin Neurophysiol. 1984 May. 57(5):423-6. [Medline].

Weissenborn K, Kolbe H. The basal ganglia and portal-systemic encephalopathy. Metab Brain Dis. 1998 Dec. 13(4):261-72. [Medline].

Weissenborn K, Scholz M, Hinrichs H, et al. Neurophysiological assessment of early hepatic encephalopathy. Electroencephalogr Clin Neurophysiol. 1990 Apr. 75(4):289-95. [Medline].

Yen CL, Liaw YF. Somatosensory evoked potentials and number connection test in the detection of subclinical hepatic encephalopathy. Hepatogastroenterology. 1990 Jun. 37(3):332-4. [Medline].

Yurdaydin C, Karavelioglu D, Onaran O, et al. Opioid receptor ligands in human hepatic encephalopathy. J Hepatol. 1998 Nov. 29(5):796-801. [Medline].

Zullo A, Rinaldi V, Meddi P, et al. Helicobacter pylori infection, plasma ammonia levels, and psychometric testing in cirrhotic patients. Am J Gastroenterol. 1999 Aug. 94(8):2214-8. [Medline].

Gagan K Sood, MD Associate Professor, Department of Medicine and Surgery, Baylor College of Medicine

Gagan K Sood, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American Gastroenterological Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous coauthor, Blake A Jones, MD, to the development and writing of this article.

Portosystemic Encephalopathy

Research & References of Portosystemic Encephalopathy|A&C Accounting And Tax Services